enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)

CUSIP: 29286M113

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / *W EXP 10/31/202
Total 13F shares
4,440,160
Share change
+3,965,084
Total reported value
$3,691,565
Price per share
$0.85
Number of holders
21
Value change
+$3,287,750
Number of buys
20

Quarterly Holders Quick Answers

What is CUSIP 29286M113?
CUSIP 29286M113 identifies ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Forbion Growth Sponsor FEAC I B.V.
3/4/5
10%+ Owner —
mixed-class rows
5,502,338
mixed-class rows
 — — 31 Oct 2023
3/4/5
Forbion Capital Fund III Cooperatief U.A.
3/4/5
10%+ Owner —
class O/S missing
2,894,735
 — — 31 Oct 2023
3/4/5
Jason David Hanson
3/4/5
Chief Executive Officer, Director —
class O/S missing
512,826
 — — 31 Oct 2023
3/4/5
Richard P. Bryce
3/4/5
Chief Medical Officer —
class O/S missing
153,000
 — — 30 Nov 2023
3/4/5
James C. Sullivan
3/4/5
Chief Scientific Officer —
class O/S missing
118,509
 — — 31 Oct 2023
3/4/5
BVF PARTNERS L P/IL
3/4/5
10%+ Owner —
class O/S missing
104,257
 — — 31 Oct 2023
3/4/5

Institutional Holders of enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW) as of Q4 2023

As of 31 Dec 2023, enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,440,160 shares. The largest 10 holders included BVF INC/IL, HIGHBRIDGE CAPITAL MANAGEMENT LLC, Omega Fund Management, LLC, Blue Owl Capital Holdings LP, FCPM III SERVICES B.V., Calamos Advisors LLC, COWEN AND COMPANY, LLC, AQR Arbitrage LLC, TENOR CAPITAL MANAGEMENT Co., L.P., and D. E. Shaw & Co., Inc.. This page lists 21 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2023 vs Q3 2025 Across Filers

Q3 2025 holders
17
Q4 2023 holders
21
Holder diff
4
Investor Q3 2025 Shares Q4 2023 Shares Share Diff Share Chg % Q3 2025 Value $ Q4 2023 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.